Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 97.90% is 36% above its 1-year average of 71.95%, near the high end of its 1-year range (0.00%–100.00%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 88.58%.
GROSS MARGIN
97.90%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 854 covered companies
CURRENT VS SECTOR MEDIAN
+137.59%
vs the sector median at left
Market Cap
$137.05M
Gross Margin
61.99%
TTM Avg
62.83%
3Y Avg
59.84%
5Y Avg
59.96%
Market Cap
$134.83M
Gross Margin
3.67%
TTM Avg
16.70%
3Y Avg
18.97%
5Y Avg
8.54%
Market Cap
$139.08M
Gross Margin
81.26%
TTM Avg
40.63%
3Y Avg
20.32%
5Y Avg
13.54%
Market Cap
$133.33M
Gross Margin
57.63%
TTM Avg
59.89%
3Y Avg
61.87%
5Y Avg
62.78%
Market Cap
$140.49M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
12.53%
5Y Avg
23.21%
Market Cap
$132.64M
Gross Margin
33.47%
TTM Avg
39.70%
3Y Avg
43.04%
5Y Avg
44.80%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | $137.36M | 97.90% | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.05M | 61.99% | 62.83% | 59.84% | 59.96% |
| Freenome, Inc. (FRNM)vs › | $135.61M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $134.83M | 3.67% | 16.70% | 18.97% | 8.54% |
| LifeMD, Inc. (LFMD)vs › | $134.21M | 85.91% | 84.21% | 85.09% | 82.87% |
| Alpha Cognition Inc (ACOG)vs › | $139.08M | 81.26% | 40.63% | 20.32% | 13.54% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $133.33M | 57.63% | 59.89% | 61.87% | 62.78% |
| Immuneering Corporation (IMRX)vs › | $140.49M | 0.00% | 0.00% | 12.53% | 23.21% |
| Health Catalyst, Inc. (HCAT)vs › | $132.64M | 33.47% | 39.70% | 43.04% | 44.80% |
| Sutro Biopharma, Inc. (STRO)vs › | $140.51M | 97.20% | 90.61% | 91.14% | 61.44% |
Gross Margin
97.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 88.58% |
| 2026-03-31 | 99.23% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 0.00% |
